Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 5/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21884509 | 0.90 | XDH (0.60) | XDHMAOB | |
| SCHEMBL24066320 | 0.85 | XDH (0.50) | XDHMAOBMRGPRX4 | |
| SCHEMBL21884495 | 0.82 | XDH (0.47) | XDHMAOB | |
| SCHEMBL23875025 | 0.82 | XDH (0.53) | XDHMRGPRX4 | |
| SCHEMBL21885715 | 0.81 | MRGPRX4 (0.48) | XDHMAOBMRGPRX4 | |
| SCHEMBL21884802 | 0.78 | XDH (0.44) | XDHMAOB | |
| SCHEMBL23874972 | 0.75 | XDH (0.55) | XDHMAOBMRGPRX4 | |
| SCHEMBL1534077 | 0.75 | XDH (0.55) | XDHMAOBMRGPRX4 | |
| SCHEMBL24066321 | 0.75 | XDH (0.52) | XDHMAOBMRGPRX4 | |
| SCHEMBL11519443 | 0.75 | FOLH1 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2020061473-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | XDH 1075/4885MAOB 2027/4885MRGPRX4 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.